Abstract
lial markers, pan-cytokeratin and prostate-specific antigen (PSA), and with TXS. Immunoreactivity for TXS was observed in the stroma and the epithel. TXS immunoreactivity colocalized with calponin, and pancytokeratin. CONCLUSIONS: The receptor antagonist picotamide inhibits 1-adrenergic, TXA2-mediated, and EFS-induced contractions in the human prostate. To the best of our knowledge, this is the first antagonist showing simultaneous interventions into different contraction systems of the prostate. In vivo studies are mandatory to examine urodynamic effects of picotamide, and to assess its efficacy for the treatment of LUTS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
